Some Providers Prescribe Unapproved Retatrutide for Weight-Loss at Alarming Rate

Despite no FDA approval or official assessment of safety and efficacy, various US providers have begun prescribing and promoting the use of retatrutide for weight loss, according to a CBS News report.¹

“The excitement surrounding emerging obesity therapies is understandable, especially when early clinical trial results appear promising,” Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, professor of pharmacy practice at the Massachusetts College of Pharmacy and Health Sciences and co-host of Drug Topics® Wicked Good Cardiometabolic Chat podcast, said. “However, until a medication completes the regulatory review process, important questions may remain regarding long-term safety, appropriate dosing, drug interactions, adverse effects, and patient selection.”

A CBS News investigation recently identified more than 120 websites and over 50 clinics across the US that are actively selling or promoting this unapproved medication. Although some operations are run by online vendors, many are staffed by licensed physicians and nurse practitioners who claim that the clinical evidence is strong enough to bypass the standard regulatory timeline.¹

Some providers, such as Jack Mutnick of Renew Med Spa Plus, have defended their decision by stating that they are confident in Eli Lilly’s clinical trial results and believe patients should not have to wait for the official government stamp. However, this practice casts aside decades of drug regulation lessons under the guise of medical freedom, potentially leading patients into dangerous territory.

READ MORE: GLP-1s Cut ER Visits, CVD Risk in Patients With Obesity

“As health care professionals, we have a responsibility to practice evidence-based medicine,” continued Goldman. “Prescribing, compounding, or distributing versions of medications that have not received FDA approval bypasses important safeguards designed to protect patients. Innovation is essential, but it must occur through the clinical trial and regulatory process.”

The scientific allure of retatrutide lies in its unique mechanism as a unimolecular agonist at the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 (GLP-1), and glucagon receptors.^2-4

This triple agonist approach is designed not only to regulate satiety but also to increase energy expenditure and lipid catabolism.^2,4,5

The TRIUMPH-1 phase 3 trial reported an average weight loss of 28.3% over 80 weeks at the 12 mg dose, with nearly half of the participants losing 30% or more of their body weight.^2,6

Despite these impressive trial-level outcomes, the drug remains strictly investigational. Official regulatory submission is not anticipated until late 2026, with a projected market launch unlikely before early 2028.^2,4,6

“Experimental drugs that have not yet been approved do not have the same level of evidence or oversight,” said Goldman. “When patients obtain unapproved products, they are accepting risks that are often not fully understood.”

For pharmacists, the rise of an illegal marketplace for retatrutide presents a significant public health hazard characterized by research-grade labeling and compounding violations. The FDA has been clear that retatrutide cannot be used in compounding under federal law because it is not a component of any FDA-approved drug.^2,3

Some clinics attempt to navigate this gray area by sourcing products labeled for research purposes only or “not for human consumption,” a tactic intended to shield sellers from legal liability while the product is distributed for human use with dosing instructions.^1,3

Using such counterfeit or unapproved medications carries severe risks, including exposure to unknown ingredients, harmful contaminants, or incorrect concentrations of the active ingredient.^4,5

The safety consequences of this unregulated use are already surfacing in poison control data. Human exposures to retatrutide reported to US poison centers surged by 265% in the first 4 months of 2026 compared with the end of 2025.¹

Beyond immediate reactions, long-term concerns regarding thyroid C-cell tumors, pancreatitis, and treatment-emergent psychiatric events like depression and suicidal ideation necessitate the rigorous monitoring that only comes with an approved regulatory framework, according to the Journal of the American College of Clinical Pharmacy.⁷

Pharmacists are uniquely positioned to intervene and assess eligibility for approved therapies and guide patients away from unauthorized therapy. They must also remain vigilant for quality issues, such as compounded GLP-1 versions that arrive warm or poorly refrigerated, which can compromise drug quality.^2,3,7

Clinical pharmacists must bridge the gap between media hype and regulatory reality.^2,7

By staying informed on the evolving trial data and the legal boundaries of the Food, Drug, and Cosmetic Act, pharmacists can protect their patients from the risks of a commercial marketplace that currently operates without the essential guardrails of federal safety, efficacy, and purity assessments. Acknowledging that the only legal pathway to retatrutide is currently through clinical trial enrollment is vital for patient safety.^2,4,5,7

“Patients should never have to choose between access and safety,” concluded Goldman in an exclusive interview. “Experimental medications belong in clinical trials until the FDA determines they are safe, effective, and appropriate for routine clinical use. Bypassing that process exposes patients to risks that neither they nor their healthcare providers can fully quantify.”

READ MORE: Obesity Resource Center

REFERENCES

1. Gilbert D, Yamaguchi A, Geller L. This weight-loss drug hasn’t been approved by the FDA. Doctors are prescribing it anyway. CBS News. June 8, 2026. Accessed June 9, 2026. https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/

2. Nowosielski B. Retatrutide exhibits meaningful weight loss in phase 3 trial. Drug Topics. May 21, 2026. Accessed June 9, 2026. https://www.drugtopics.com/view/retatrutide-exhibits-meaningful-weight-loss-in-phase-3-trial

3. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. FDA. February 4, 2026. Accessed June 9, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

4. What to know about retatrutide: an investigational triple hormone receptor agonist. Eli Lilly and Company. June 6, 2026. Accessed June 9, 2026. https://www.lilly.com/news/stories/what-to-know-about-retatrutide

5. Aungst C. 7 things to know about retatrutide for weight loss: dosages, clinical trial results, and more. GoodRx. December 11, 2025. Accessed June 9, 2026. https://www.goodrx.com/conditions/weight-loss/retatrutide-weight-loss

6. Retatrutide FDA approval status: June 2026 update. Reta. June 9, 2026. Accessed June 9, 2026. https://www.retaweightloss.com/article/retatrutide-approval-status-2026-monthly-update

7. Lingow S, Carris N, Clements J, et al. The pharmacist’s role in the use of incretin‐based therapies for weight management: an opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. JACCP. 2025;8(10):1078-1093. https://doi.org/10.1002/jac5.70111